Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, urokinase plasminogen activator in non-skull base chordoma

American Journal of Clinical Pathology

Volumn 122, Issue 6, 2004, Pages 926-930

  Naka, Takahiko ^a,c   Boltze, Carsten ^a   Kuester, Doerthe ^a   Schulz, Torss Oliver ^a   Samii, Amir ^b   Herold, Christian ^b   Ostertag, Helmut ^b   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

^c KYUSHU ROSAI HOSPITAL   (Japan)

Author keywords

Cathepsin B; Chordoma; Matrix metalloproteinase; Prognosis; Urokinase plasminogen activator

Indexed keywords

CATHEPSIN B; CYTOKERATIN 8; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; UROKINASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CHORDOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPATHOLOGY; DISEASE ASSOCIATION; DISEASE MARKER; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 9644295582     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/C8T7APJDAUPR8TLL     Document Type: Article

References (20)

1. Haeckel CG, Krueger S, Grote H-J, et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer. 2000;89:995-1003.
2. Haeckel C, Czerniak B, Ayala AG, et al. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer. 1997;79:53-58.
3. Kawashima A, Okada Y, Nakanishi I, et al. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol. 1996;142:129-137.
4. Sakamoto A, Oda Y, Iwamoto Y, et al. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol. 1999;125:541-548.
5. Ueda Y, Imai K, Tsuchiya H, et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol. 1996;148:611-622.
6. Haeckel C, Krueger S, Kuester D, et al. Expression of cathepsin K in chordoma. Hum Pathol. 2000;31:834-840.
7. O'Connell JX, Renard LG, Liebsch NJ, et al. Base of skull chordoma: a correlative study of histologic and clinical features of 62 cases. Cancer. 1994;74:2261-2267.
8. Volpe R, Mazabraud A. A clinicopathologic review of 25 cases of chordoma: a pleomorphic and metastasizing neoplasm. Am J Surg Pathol. 1983;7:161-170.
9. Bergh P, Kindblom L, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-2134.
10. Holton J, Steel T, Luxsuwong M, et al. Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Appl Neurobiol. 2000;26:497-503.
11. Kumaki F, Matsui K, Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001;159:2125-2135.
12. Sier CFM, Kubben FJGM, Ganesh S, et al. Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74:413-417.
13. Herszenyi L, Plebani M, Carraro P, et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 1999;86:1135-1142.
14. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996;2:461-462.
15. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol. 1997;28:613-622.
16. Young TN, Rodriguez GC, Rinehart AR, et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol. 1996;62:89-99.
17. Kallakury BVS, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113-3119.
18. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. J Pathol. 1998;185:256-261.
19. Naka T, Boltze C, Samii S, et al. Skull base and non-skull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003;98:1934-1941.
20. Naka T, Iwamoto Y, Shinohara N, et al. Cytokeratin subtyping in chordomas and fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol. 1997;10:545-551.